Explore the tumultuous first 100 days of Donald Trump's presidency, marked by tariff negotiations with China, a controversial Harvard funding cut, and plummeting approval ratings.
In a groundbreaking decision, a federal judge has approved a settlement allowing college athletes to be directly compensated by their schools for the first time. This landmark change will reshape college sports and athlete rights.
Follow the latest updates on President Trump's first 100 days, including tariffs with China, declining approval ratings, and a contentious funding battle with Harvard University.
Paramount Global has scheduled its annual shareholder meeting for July 2, signaling potential delays in its $8 billion merger with Skydance Media. With regulatory hurdles and a lawsuit from Donald Trump, the merger's future remains uncertain.
In a groundbreaking move, the FDA has approved Moderna's lower-dose Covid-19 vaccine for older adults and at-risk individuals. Get ready for a new option this fall as Moderna targets the LP.8.1 variant!
The U.S. has approved Moderna's new COVID-19 vaccine, mNexspike, specifically for high-risk groups. This innovative option offers a lower dose while maintaining effectiveness, marking a pivotal step in the fight against coronavirus.
In a significant ruling, the 9th Circuit Court has frozen President Trump's mass firings directive at multiple agencies, marking a setback for his plans to reshape the federal government. The court emphasized that such drastic measures require congressional authorization.
In a shocking turn, President Trump endorses Nippon's $15 billion bid for U.S. Steel, contradicting his earlier stance and igniting concerns over American jobs and national security. The United Steelworkers union reacts strongly, calling it a betrayal.
Explore the highs and lows of Donald Trump's presidency as we track his progress on campaign promises, legal battles, and the ongoing tariff negotiations with China. Discover the latest on the Harvard funding feud and public opinion.
In a groundbreaking achievement, scientists have developed the first gene-editing medicine tailored for a baby suffering from a rare DNA condition. After successful treatments, KJ Muldoon is now healthier and ready to go home, showcasing a promising future for gene therapies.
